Feng-Yi Ke

742 total citations · 1 hit paper
7 papers, 426 citations indexed

About

Feng-Yi Ke is a scholar working on Infectious Diseases, Molecular Biology and Ecology. According to data from OpenAlex, Feng-Yi Ke has authored 7 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 3 papers in Molecular Biology and 1 paper in Ecology. Recurrent topics in Feng-Yi Ke's work include SARS-CoV-2 and COVID-19 Research (4 papers), COVID-19 Clinical Research Studies (2 papers) and SARS-CoV-2 detection and testing (2 papers). Feng-Yi Ke is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), COVID-19 Clinical Research Studies (2 papers) and SARS-CoV-2 detection and testing (2 papers). Feng-Yi Ke collaborates with scholars based in Taiwan. Feng-Yi Ke's co-authors include Kang-Hao Liang, Han‐Chung Wu, Shih-Chieh Su, Shih-Han Ko, Ruei‐Min Lu, Yi‐Ping Wang, Pan‐Chyr Yang, Chia-Ching Lin, Hsin‐Jung Li and Ya‐Hsuan Chang and has published in prestigious journals such as Cancer Research, Cancer Letters and Heliyon.

In The Last Decade

Feng-Yi Ke

7 papers receiving 420 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

2022 157 citations Ruei‐Min Lu, Shih-Chieh Su et al. Journal of Biomedical Science profile →

Peers

Countries citing papers authored by Feng-Yi Ke

Since Specialization

Citations

This map shows the geographic impact of Feng-Yi Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng-Yi Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng-Yi Ke more than expected).

Fields of papers citing papers by Feng-Yi Ke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng-Yi Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng-Yi Ke. The network helps show where Feng-Yi Ke may publish in the future.

Co-authorship network of co-authors of Feng-Yi Ke

This figure shows the co-authorship network connecting the top 25 collaborators of Feng-Yi Ke. A scholar is included among the top collaborators of Feng-Yi Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng-Yi Ke. Feng-Yi Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Developing a delivery strategy for combined drug treatment with multi-targeting immunoliposomes 2024 ·Journal of Drug Delivery Science and Technology ·Monika Kumari, (unknown), Feng-Yi Ke, Peter H. Pan, (unknown), (unknown), Han‐Chung Wu	2
2	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice 2023 ·Heliyon ·Ruei‐Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu‐Fei Hsu, Hsiu-Ting Lin, (unknown), Feng-Yi Ke, Monika Kumari, Yu‐Chi Chou, Mi‐Hua Tao, Yi‐Ling Lin, Han‐Chung Wu	4
3	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies 2022 ·Journal of Biomedical Science ·Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, Jhih‐Liang Huang, Fu‐Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, (unknown), Hsiao-Ling Chiang, Cheng‐Pu Sun, (unknown), Wen‐Shan Li, Hsing‐Pang Hsieh, Mi‐Hua Tao, Han‐Chung Wu	94
4	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection breakdown → 2022 ·Journal of Biomedical Science ·(unknown), Ruei‐Min Lu, Shih-Chieh Su, (unknown), Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, (unknown), Han‐Chung Wu	157
5	Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants 2022 ·Journal of Biomedical Science ·Shih-Han Ko, Chen Wy, Shih-Chieh Su, Hsiu-Ting Lin, Feng-Yi Ke, Kang-Hao Liang, Fu‐Fei Hsu, Monika Kumari, (unknown), Han‐Chung Wu	7
6	ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling–Driven Epithelial-to-Mesenchymal Transition 2021 ·Cancer Research ·Hsin‐Jung Li, Feng-Yi Ke, Chia-Ching Lin, (unknown), (unknown), Yi‐Ping Wang, Kang-Hao Liang, (unknown), Ya‐Hsuan Chang, Hsuan‐Yu Chen, Pan‐Chyr Yang, Han‐Chung Wu	101
7	Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells 2018 ·Cancer Letters ·Kang-Hao Liang, (unknown), (unknown), (unknown), (unknown), Feng-Yi Ke, Yi‐Ting Chuang, I-Ju Liu, Yi‐Ping Wang, Ruey‐Hwa Chen, Han‐Chung Wu	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact